The diagnostic is the deliverable.

I have watched this pattern for two decades from inside the buyer's chair. A firm gets hired, runs a three-week "discovery" that is mostly a set of polite interviews with the leadership team, and then delivers a strategy deck that tells the company what it already half-believes about itself, organized more neatly. The deck gets presented, nods are exchanged, and six months later very little has changed. The CEO is mildly disappointed, the consultant is mildly defensive, and the company is several hundred thousand dollars lighter with no structural shift to show for it.

The diagnosis was skipped. That is why the prescription did not hold.

Why consultants skip the diagnostic

It is not because consultants are lazy or unskilled. The incentives push against it.

Diagnostics are uncomfortable. They surface things the leadership team does not want to hear. They show that the stated ICP is aspirational, that the empirical ICP is narrower and less glamorous, that the reason the pipeline is thin is not the marketing team but the positioning, that the real competitor is not the named one but the status quo, that the win rate by segment tells a different story than the quarterly narrative. None of that is fun to present to a CEO who hired you to help them scale.

Diagnostics are also slow relative to the timeline clients are trained to expect. A proper diagnostic takes three to four weeks of real work, not two weeks of interviews and a synthesis. That is hard to sell because the client wants to see momentum, and a diagnostic looks, from the outside, like the consultant has not done anything yet.

So consultants compress. They run the discovery on the surface, extract the working hypothesis the leadership team already holds, and then decorate that hypothesis with frameworks and formatting. The client gets a version of their own thinking reflected back at them with more polish, and the engagement feels successful in the room and fails in the market.

What a real diagnostic does

A real diagnostic asks seven questions, and the answers should sometimes surprise both the consultant and the client.

Who is actually buying this product, as distinct from who the company says its target is? The gap between those two is usually the first real finding. When the stated ICP is "large enterprise financial services" and eighty percent of closed-won deals come from mid-market insurance and regional banks, the company does not have an ICP problem. It has a self-awareness problem.

Why are deals actually being won and lost? The closed-lost data, read carefully, tells you more about your positioning than any exercise does. The patterns in why customers walk are where the honest insights live.

Where is the funnel actually leaking? Not in the aggregate, by segment and by source. Most funnels have one or two places where the leak is enormous and several places where the numbers are fine. Pretending the leak is uniform leads to uniform solutions, which do not work.

Does the positioning pass the alternatives test? Not "how do we compare to our named competitors," but "what does the buyer actually consider, and does our positioning make sense in that set?" In security, the real alternative is often "do nothing" or "use what the cloud platform gives us for free." A positioning that assumes a head-to-head competitive frame when the real frame is "buy anything at all" will not convert.

Is the motion appropriate for the segment? Companies routinely run a high-touch enterprise motion against mid-market buyers who want self-serve, or a product-led motion in a category where buyers demand executive engagement. The motion mismatch is invisible until you look for it.

Is the org built for the motion? Marketing teams weighted toward demand gen when the problem is product marketing. SDR teams hunting in segments the data says do not convert. No partner function in a category that has always been partner-led. These show up in the diagnostic and never in the strategy brief.

Is the pricing aligned with the value delivered and the way the buyer wants to buy? Pricing is the last place most engagements look and often the first place the leverage is.

When you answer these seven questions honestly, the strategy writes itself. When you skip them, the strategy is a guess dressed as a plan.

Why this matters for scaling companies

There is a specific moment in a B2B technology company's arc where this all comes to a head. Somewhere between thirty and fifty million in ARR, the growth motion that got the company here starts to break. Deals take longer to close. Win rates in what you thought was the core segment start to drift. Expansion slows. The leadership team feels it before the data confirms it.

The instinct in that moment is to act. Add headcount. Launch a campaign. Hire a new CRO. Commission a GTM strategy refresh. All of these are reasonable. None of them work if the underlying diagnosis is wrong.

The companies that break through that stall are the ones that slow down enough to diagnose honestly, and then move fast on the two or three things that actually matter. The companies that stall longer are the ones that skipped the diagnosis and are now executing harder on a plan built on the wrong thesis.

What to do instead

If you are considering a GTM engagement, ask the firm how they run the diagnostic. If the answer is a two-week discovery sprint and a synthesis workshop, you are buying strategy decoration. If the answer is a structured evaluation of ICP empirics, funnel performance by segment, closed-lost pattern analysis, positioning audit against actual buyer alternatives, and org-to-motion fit, you are buying something that might actually change the trajectory.

The deliverable of a good diagnostic is not a deck. It is two or three sentences that honestly describe what is constraining growth. If those sentences are uncomfortable to read, the diagnostic probably did its job. If they are comfortable, it probably did not.

The strategy is downstream of that. Get the diagnosis right, and the strategy becomes the obvious set of moves. Skip it, and no amount of strategic sophistication will save the engagement.